Seeking Alpha

MissionIR's  Instablog

MissionIR
Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
MissionIR
My blog:
MissionIR Blog
  • iBio, Inc. (IBIO) Receives U.S. Patent for iBioLaunch Platform that Causes Non-transgenic Plants to Rapidly Produce Proteins 0 comments
    Oct 31, 2011 5:37 PM | about stocks: IBIO

    iBio, Inc., a leader in the plant-made pharmaceutical field, today announced that the U.S. Patent and Trademark Office has issued a patent that covers the viral vectors comprising the iBioLaunch™ platform. iBio owns this proprietary technology that was developed by scientists at iBio’s research collaborator, the Fraunhofer USA Center for Molecular Biotechnology (Fraunhofer).

    The iBioLaunch™ platform is a highly flexible technology that easily, cheaply and reliably causes non-tangenic plants to rapidly produce a large amount of recombinant protein in the plant biomass for biotherapeutics and vaccines. This whole plant approach allows for lower operating and capital expenses versus protein production using engineered microbial or animal cells in bioreactors. It also has both commercial and public safety advantages, as well as scalability, no risk of contamination by animal pathogens and the ability to show complex proteins.

    “The issuance of this patent substantially strengthens the intellectual property foundation of the iBioLaunch system for simultaneously expressing more than a single protein,” said Terence Ryan, Ph.D., iBio’s Senior Vice-President in a press release on Monday. “For example, this patent protects the technology we use for production of human monoclonal antibodies, a rapidly growing pharmaceutical category in which we recently announced successful product candidate testing.”

    iBio continues to establish licenses or other collaboration arrangements for its biosimilar products and proprietary products as it moves to commercialize its technology. In January, iBio and Fraunhofer entered into a license and collaboration agreement with an entity linked to the Health Ministry of Brazil to develop and sell a proprietary yellow fever vaccine created with iBioLaunch technology to replace chicken egg based vaccine products.

    For more information, please visit www.ibioinc.com

    Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

    Stocks: IBIO
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.